Plain Language Summary

Boswellia serrata (Indian frankincense) is a resin with clinically demonstrated anti-inflammatory effects, particularly for joint conditions and inflammatory bowel disease. Its mechanism is distinct from NSAIDs, making it of interest for patients who cannot tolerate standard anti-inflammatory drugs.

What It Is

Boswellia serrata is a large tree native to India, Africa, and the Arabian Peninsula. Its resin (frankincense) has been used medicinally for thousands of years. Active compounds include boswellic acids, particularly AKBA (3-O-acetyl-11-keto-beta-boswellic acid), which are the primary anti-inflammatory agents.

Traditional Uses

  • Joint inflammation
  • Asthma
  • Inflammatory bowel conditions
  • Skin disorders
  • Memory

Mechanism of Action

Boswellic acids inhibit 5-lipoxygenase (5-LOX), an enzyme in the leukotriene inflammatory pathway. This is a different anti-inflammatory mechanism than NSAIDs (which inhibit COX enzymes), meaning boswellia may be used where NSAIDs are contraindicated. Also inhibits human leukocyte elastase (HLE) and reduces pro-inflammatory cytokines.

Human Research Highlights

  • Multiple RCTs and a systematic review demonstrate significant pain reduction and functional improvement in knee osteoarthritis.
  • A 2014 Cochrane review found moderate evidence for short-term benefit in knee osteoarthritis.
  • Two RCTs in Crohn's disease showed improvement in disease activity indices comparable to mesalazine.
  • A small RCT showed benefit in ulcerative colitis remission maintenance.
  • Evidence for asthma: one RCT found reduced frequency of attacks and improved lung function.
  • AKBA-enriched formulations (5-LOXIN, ApresFlex) show more consistent results than standard extracts.

Preclinical & Laboratory Research

  • Animal models confirm anti-inflammatory, antiarthritic, and antitumor activities.
  • In vitro cancer research across several cancer lines, not replicated in humans.

Dosage Studied

300-400 mg standardized extract (containing 30-65% boswellic acids) 2-3 times daily. AKBA-enriched extracts (5-LOXIN, ApresFlex) studied at 100-250 mg daily.

Safety Notes

  • Generally well tolerated. Side effects are mild: nausea, diarrhea, and skin rash in some individuals.
  • No significant liver toxicity reported in clinical trials.
  • May interact with anticoagulants at high doses.
  • Limited data in pregnancy and breastfeeding - avoid unless medically supervised.

Drug Interactions

  • Anticoagulants (warfarin): potential additive effect at high doses
  • NSAIDs: may have complementary anti-inflammatory effects, but clinical significance unclear

Research Gaps

  • Large, long-term RCTs in osteoarthritis still needed.
  • IBD evidence is promising but from small trials.
  • Optimal AKBA standardization level not established.
  • Comparative effectiveness vs. NSAIDs not well-studied.

Clinical Relevance

Boswellia is a reasonable evidence-based option for inflammatory joint conditions, particularly in patients who do not tolerate NSAIDs. IBD applications show promise but require larger trials. Its 5-LOX inhibition mechanism offers a complementary approach to standard anti-inflammatory therapies.

Citations

  1. Majeed M et al. Boswellic acids: Novel multi-target inhibitors of pain and inflammation. J Pharmacogn Phytochem. 2017.
  2. Sengupta K et al. A Double Blind, Randomized, Placebo Controlled Study of the Efficacy and Safety of 5-Loxin for Treatment of Osteoarthritis of the Knee. Arthritis Res Ther. 2008.
  3. Gupta I et al. Effects of Boswellia serrata gum resin in patients with ulcerative colitis. Eur J Med Res. 1997.

Disclaimer: Educational information only. Not medical advice. Consult a qualified healthcare professional before use.

Last updated: March 1, 2025